Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00222495 · ClinicalTrials.gov registry record · NA
A Comparative Study of New Medications for Psychosis in Adolescents
A NA study, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00222495: Completed NA study, sponsored by University of Minnesota.
NCT00222495 is a NA study that has completed, run by University of Minnesota. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00222495, a NA study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The overall goal of this study is to determine the efficacy and tolerability of three atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) in the treatment of adolescents with psychosis. It is hypothesized that the three medications will be equally effective in reducing the symptoms of psychosis.
Interventions
- DRUG risperidone
- DRUG olanzapine
- DRUG quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-08 |
| Est. Completion | 2006-08 |
| Phase | NA |
What the finished NCT00222495 record still lists
NCT00222495 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which risperidone is the first listed.
NCT00222495 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00222495 about?
NCT00222495 is a clinical study titled "A Comparative Study of New Medications for Psychosis in Adolescents". The overall goal of this study is to determine the efficacy and tolerability of three atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) in the treatment of adolescents with psychosis. It is hypothesized that the three medications will be equally effective in reducing the s...
What is the current status of trial NCT00222495?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2002-08. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00222495?
The interventions under investigation include: risperidone (DRUG), olanzapine (DRUG), quetiapine (DRUG).
Who is sponsoring clinical trial NCT00222495?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00222495's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia